LA-CB1

Description

LA-CB1 is an Abemaciclib HY-16297A derivative that targets CDK4/6 and promotes its degradation via the ubiquitin-proteasome pathway, thereby disrupting the CDK4/6-Cyclin D1-Rb-E2F axis and inducing G0/G1 cell cycle arrest and apoptosis. LA-CB1 exhibits antiproliferative activity against MDA-MB-231 cells, with an IC50 of 0.27 AAasAasAAmuM, and effectively inhibits epithelial-mesenchymal transition EMT , cell migration, invasion, and angiogenesis. In highly aggressive models such as triple-negative breast cancer TNBC , LA-CB1 significantly suppresses tumor growth in a dose-dependent manner. LA-CB1 holds potential for research in the field of breast cancer.